Welcome to our dedicated page for Flexsteel Inds SEC filings (Ticker: FLXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
From its signature steel drop-in seat spring to its multi-channel distribution network, Flexsteel’s story is woven through every disclosure it files. If you’ve ever typed “Flexsteel SEC filings explained simply” or wondered how freight costs affect margins, you know the challenge: hundreds of pages, layered accounting notes, and form types that read like code numbers.
Stock Titan solves that. Our AI reads each “Flexsteel annual report 10-K simplified” as soon as it hits EDGAR, pinpoints raw-material price sensitivity, and surfaces the upholstery mix by segment. Need the latest “Flexsteel quarterly earnings report 10-Q filing”? We extract backlog trends and cash-flow swings in seconds. Material event on tariffs? The “Flexsteel 8-K material events explained” tag directs you to the exact paragraph. And when executives trade shares, real-time alerts on “Flexsteel insider trading Form 4 transactions” keep you informed before markets digest the news.
Whether you’re tracking cost inflation or comparing channel sales, our platform offers:
- AI-powered summaries that make “understanding Flexsteel SEC documents with AI” effortless
- Immediate access to “Flexsteel Form 4 insider transactions real-time” and “Flexsteel executive stock transactions Form 4”
- Clear charts for “Flexsteel earnings report filing analysis” across quarters
- One-click view of the latest “Flexsteel proxy statement executive compensation” for pay-for-performance insights
No more manual searches across filings; just the data that matters, delivered in context, ready to support investment decisions.
Flexsteel Industries (FLXS) – Form 4 insider activity
On 30 June 2025, VP-Human Resources Stacy Marie Kammes exercised 2,600 previously granted restricted stock units (RSUs). After automatic share withholding of 1,211 shares at $36.03 for tax purposes, her direct common-stock ownership rose by a net 1,389 shares to 25,256.
In addition, on 1 July 2025 she received a new award of 2,278 service-based RSUs that will vest in three equal tranches on 30 June 2026, 2027 and 2028, encouraging continued retention.
No cash transactions or open-market sales occurred; all activity relates to equity compensation. The filing does not disclose any changes to corporate strategy, earnings, or guidance, and therefore has limited direct impact on valuation.
Synchrony Financial (SYF) filed a Form 4 on 2 Jul 2025 disclosing a routine equity award to director Fernando Aguirre. On 30 Jun 2025 Aguirre received 825 restricted stock units (RSUs) classified under transaction code “A” (grant). The filing lists an indicative price of $66.74, though RSUs do not require cash payment. The award will vest in full on 30 Jun 2026; each RSU converts into one share of SYF common stock.
Following the grant, Aguirre’s direct ownership rises to 27,097 common shares. He also reports 15,300 shares held indirectly through family trusts, bringing his total reported economic exposure to 42,397 shares. No open-market purchases, sales, or derivative transactions were reported, and there were no amendments to previous filings.
The size of the award represents a modest increase—roughly 3% of Aguirre’s previously reported direct holdings and an immaterial fraction of SYF’s ~420 million shares outstanding. As such, the transaction is viewed as a standard board compensation event that marginally aligns director incentives with shareholder interests but carries no material impact on the company’s capital structure or valuation.
Centene Corporation (CNC) – Form 4 insider activity
Director Christopher J. Coughlin reported one transaction dated 30 June 2025. He acquired 556 shares of Centene common stock at a stated price of $0, indicating the shares were received without cash consideration (e.g., settlement of equity awards as reflected by the filing). Following the transaction, Mr. Coughlin’s direct holdings increased to 11,435.926 shares. The filing also discloses indirect ownership of 30,054 shares held in a grantor-retained annuity trust (GRAT) for the benefit of Mr. Coughlin and his adult children, for which he is sole trustee.
Table II lists a previously granted option for 10,000 shares with a $80.57 exercise price, exercisable beginning 7 Feb 2025 and expiring 7 Feb 2032. No new derivative transaction was reported in this filing.
Key takeaways for investors
- The filing records a modest increase in insider ownership without any share sales.
- Cumulative direct and indirect equity exposure now totals ~41,490 shares, aligning director interests with shareholders.
- No material change to option positions; the 10,000-share option remains outstanding.
The transaction is routine in size relative to Centene’s market capitalization but may be interpreted as a marginally positive signal given the absence of dispositions.
On 2 July 2025, Enstar Group Limited (symbol: ESGR) and its financing subsidiary filed Post-Effective Amendment No. 1 to six previously effective Form S-3 shelf registration statements. The amendment follows the completion of a series of mergers, effective the same day, in which Enstar became a wholly owned subsidiary of Elk Bidco Limited. Because public offerings under these shelves have been terminated, the registrants are deregistering all securities that remained unsold under the following registration numbers: 333-270204, 333-220889, 333-215144, 333-195562, 333-151461 and 333-143064. No new securities are being offered, and no financial results are provided. Signatures were executed by Audrey B. Taranto (General Counsel) for Enstar Group Limited and Jennifer Miu (Chief Financial Officer) for Enstar Finance LLC.
Ionis Pharmaceuticals (IONS) filed a Form 4 disclosing routine board compensation for non-employee director Allene M. Diaz on 07/01/2025. She received:
- 11,518 non-qualified stock options with a strike price of $39.94.
- 5,220 restricted stock units (RSUs).
Under the company’s Non-Employee Director Compensation Policy, total 2025 equity value was capped at $450,000 (ASC 718 grant-date fair value), so the awards were adjusted downward to stay within that limit.
Both the options and RSUs vest 100 % on the earlier of (i) the first anniversary of the grant or (ii) the next annual shareholder meeting. No shares are currently vested or exercisable.
After the grant, Diaz beneficially owns 11,518 derivative option securities and 9,299 RSUs, all held directly. No open-market purchases or sales occurred, and no cash changed hands; the filing reflects standard equity grants intended to align director incentives with shareholder interests.